PPARG antibody (Isoform 1, N-Term)

Catalog No. ABIN303335

The Rabbit Polyclonal anti-PPARG antibody is suitable to detect PPARG in samples from Human. It has been validated for WB, IHC (p) and EIA.

Quick Overview for PPARG antibody (Isoform 1, N-Term) (ABIN303335)

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PPARG antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Product Details anti-PPARG Antibody

Binding Specificity: AA 255-268, Isoform 1, N-Term

Purification: Immunoaffinity Chromatography.

Immunogen: Synthetic Peptide corresponding to Amino acids 255 -268 of human PPAR gamma isoform 1.

Application Details

Application Notes: Immunohistochemistry on Paraffin Sections (5 μg/mL). Western Blot. ELISA (1/8000-1/32000).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 with 0.01 % (w/v) Sodium Azide as preservative.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid cycles of freezing and thawing.

Storage: -20 °C

Storage Comment: Store vial at-20 °C prior to opening. For extended storage aliquot contents and freeze at-20 °C or below. Centrifuge product if not completely clear after standing at room temperature.

Target Details for PPARG

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Alternative Name: PPAR-gamma

Background: Since their discovery in the early 1990's, the peroxisome proliferator activated receptors (PPARs) have attracted significant attention. This is primarily because PPARs serve as receptors for two very important classes of drugs: the hypolipidemic fibrates and the insulin sensitizing thiazolidinediones. Peroxisome proliferators are non-genotoxic carcinogens that are purported to exert their effect on cells through their interaction with members of the nuclear hormone receptor family termed PPARs. Nuclear hormone receptors are ligand-dependent intracellular proteins that stimulate transcription of specific genes by binding to specific DNA sequences following activation by the appropriate ligand. Upon binding fatty acids or hypolipidemic drugs, PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate the expression of target genes. There are 3 known subtypes of PPARs: PPAR-alpha, PPAR-delta and PPAR-gamma. Mostly target genes are involved in the catabolism of fatty acids. Conversely, PPAR-gamma is activated by peroxisome proliferators such as prostaglandins, leukotrienes and anti-diabetic thiazolidinediones and affects the expression of genes involved in the storage of the fatty acids. PPAR-gamma may also be involved in adipocyte differentiation. It has also been shown that PPARs can induce transcription of acyl coenzyme A oxidase and cytochrome P450 through interaction with specific response elements.Synonyms: NR1C3, PPARG, Peroxisome proliferator-activated receptor gamma

Gene ID: 5468

NCBI Accession: NP_005028

UniProt: P37231

Pathways: MAPK Signaling, Nuclear Receptor Transcription Pathway, Steroid Hormone Mediated Signaling Pathway, Negative Regulation of Hormone Secretion, Carbohydrate Homeostasis, Regulation of Lipid Metabolism by PPARalpha, Positive Regulation of Endopeptidase Activity, Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation